PANCREATIC CANCER RECORDS REVIEW CHECKLIST
Regenerative Medicine China | 27 September 2026
https://regenerativemedicinechina.com/conditions/pancreatic-cancer/

Patient information; not a treatment plan or a guarantee of eligibility. Keep completed copies private.

KRAS G12D Pancreatic Cancer Treatment and Clinical Trials in China
[ ] Exact pathology, stage and current scan assessment.
[ ] Complete prior-treatment timeline, including RAS-targeted drugs.
[ ] Full molecular and any relevant HLA reports.
[ ] Named treatment or study, institution and current site response.
[ ] Screening, cost, follow-up and alternative-care questions answered.
https://regenerativemedicinechina.com/conditions/pancreatic-cancer/

KRAS G12D and HLA-C*08:02: what TCR-T research means for pancreatic cancer
[ ] Exact KRAS variant and full HLA allele report
[ ] Named cell product, protocol identifier and current study arm
[ ] Dated confirmation of site status and screening availability
[ ] Written list of remaining clinical and laboratory requirements
https://regenerativemedicinechina.com/guides/kras-g12d-hla-c0802-tcr-t-pancreatic-cancer-china/

Can you explore China clinical trials while taking daraxonrasib?
[ ] Pathology and full molecular report, including the exact KRAS variant if present.
[ ] Treatment timeline naming daraxonrasib and every previous anticancer therapy.
[ ] Recent scan reports, relevant laboratory results and current side effects.
[ ] Treating oncologist contact details and, where applicable, current trial details.
[ ] The proposed trial identifier, hospital, cohort and date of eligibility feedback.
https://regenerativemedicinechina.com/guides/clinical-trials-after-daraxonrasib-rmc-6236/

MSS and PD-L1-Negative Pancreatic Cancer: What to Ask About Immunotherapy
[ ] Full pathology and molecular reports, with specimen dates and assay names.
[ ] Separate entries for MMR, MSI/MSS, PD-L1 and TMB.
[ ] Unreportable or equivocal findings retained as uncertain.
[ ] Exact therapy or study linked to its own selection criteria.
[ ] Genetic-counselling questions separated from tumour-treatment questions.
https://regenerativemedicinechina.com/guides/mss-pdl1-negative-pancreatic-cancer-immunotherapy/

Preparing for pancreatic cancer clinical trial prescreening in Shanghai
[ ] Current study identifier, arm and named reviewing team
[ ] Requested records, dated medicine list and clinical summary
[ ] Confirmed secure transfer and patient permission
[ ] Written preliminary outcome, remaining tests and next contact
[ ] Screening costs, travel needs and follow-up responsibilities
https://regenerativemedicinechina.com/guides/pancreatic-cancer-clinical-trial-prescreening-shanghai/

Confirm with the responsible institution which files and tests are required. Do not change treatment to complete this checklist.